BIOCHINA 2026 BiOFUNDING Forum Agenda&Speaker

During BIOCHINA 2026, the BiOFUNDING Forum will spotlight cutting-edge investment trends and industrial collaboration opportunities in the biopharma sector. Several leading Chinese investors have already confirmed their participation.

Connect with global capital, innovative biotech companies, translational platforms, and policy makers to explore:

💡 Investment trends & cross-border fund strategies

💡 Strategic M&A & IPO value creation

💡 Early-stage innovation incubation

🔗 Register Now: BIOCHINA2026

Join us for in-depth dialogues and precise matchmaking, uncover high-potential opportunities, and drive capital deployment and ecosystem synergy in biopharma!

📌 Agenda – March 13, 2026

09:00–09:20 Global Biopharma Investment Trends: capital flows & opportunities

09:20–10:10 2026 Biopharma Investment Themes: next year’s hot directions

10:10–11:00 Cross-Border Dual-Currency Fund Strategies: global capital allocation

12:00–13:00 LP-GP Collaboration: linking policy, capital & innovation

13:00–14:00 Big Pharma Incubators: fostering innovation & win-win projects

15:00–16:00 Industrial Investment Landscape: partnerships, alliances & M&A

16:00–17:00 IPO 2.0 Era: rebuilding company value post-financing

17:00–18:00 Early-Stage Innovation: spotting & funding emerging projects

🎤 Speakers

Xiaohang Tong, Partner, Decheng Capital

Xi Yang, Chairman, Guangzhou Guoju Venture Capital

Chong Zhang, Partner, Green Pine Capital

Pai Zhu, CEO, EFUNG CAPITAL

Fei Qi, Executive Director, Junlian Capital

Di Xu, Head of China, Bayer Co.Lab

Congyang Wu, Head of Strategy & Operations, AbbVie Ventures

Peng Lin, Deputy General Manager, China Resources Biopharma

Xin Xie, Executive Director & Senior Vice President, Sino Biopharmaceutical

Yuanyuan Sun, Chief Analyst, INDUSTRIAL SECURITIES

Weimin Liu, Managing Director, BeOne Medicines